MilliporeSigma announced an additional investment of $50 million to build a robust manufacturing and distribution platform in Asia over a span of two years. This investment follows the company’s November 2016 announcement of its $100 million Life Science investment in Nantong, China.   “In biopharmaceutical research, time is of the essence,” said Udit Batra, chief executive officer, MilliporeSigma. “Our investments in the important Asian markets of South Korea, India and China ensure tha...